News

FDA Approves the First Infusion Therapy for Aggressive, Rare Blood Disease

01/21/2020

The FDA has approved tagraxofusp-erzs (Elzonris; Stemline Therapeutics) for the treatment of adults and children aged ≥2 years with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

The FDA has approved...

01/21/2020

Oncology

News

Experts Identify Factors for Poor Prognosis in Shwachman-Diamond Syndrome With MDS or AML

01/15/2020

Patients with Shwachman-Diamond syndrome and MDS or AML have a poor prognosis because of treatment-related toxicities.

Patients with Shwachman-Diamond...

01/15/2020

Oncology

News

Luspatercept Reduces Anemia Severity in Patients With MDS Receiving Transfusions

01/14/2020

Among patients with lower-risk MDS receiving regular red-cell transfusions, treatment with luspatercept reduces the severity of anemia.

Among patients with lower-risk...

01/14/2020

Oncology

News

Luspatercept Demonstrates Long-Term Safety and Efficacy for Anemia in Patients With MDS

12/27/2019

Long-term analyses of the MEDALIST study show sustained responses with durable clinical benefit in patients with MDS receiving luspatercept for anemia, superior to that of patients receiving placebo.

Long-term analyses of the...

12/27/2019

Oncology

News

Luspatercept Active in Patients with Myelofibrosis-Associated Anemia

12/27/2019

Initial results from an ongoing study suggest clinically significant activity of luspatercept for the treatment of myelofibrosis-associated anemia.

Initial results from an ongoing...

12/27/2019

Oncology

News

Ruxolitinib Plus Pomalidomide Feasible for Treatment of MF With Anemia

12/18/2019

Combining ruxolitinib therapy with pomalidomide is feasible for the treatment of patients with poor-risk MF and anemia, updated study findings show.

Combining ruxolitinib therapy...

12/18/2019

Oncology

News

Superior DFS and OS With FluMel vs FluBu in Older Patients With MDS

12/03/2019

A reduced-intensity conditioning regimen for older patients with MDS comprised of FluMel is tied to superior DFS and OS than FluBu according to data that will be presented at the 2019 ASH Annual Meeting.

A reduced-intensity conditioning...

12/03/2019

Oncology

News

NCCN Updates Guidelines for MDS

07/19/2018

The NCCN has published updates to their clinical practice guidelines for myelodysplastic syndromes, including updates to initial evaluation, additional testing, and prognostic categories.

The NCCN has published updates...

07/19/2018

Oncology

News

Alternative Therapy Superior to Standard Care in Patients With MF and Thrombocytopenia

03/13/2018

A JAK2/FLT3 inhibitor may be able to provide an alternative treatment option for patients with myelofibrosis and baseline thrombocytopenia.

A JAK2/FLT3 inhibitor may be...

03/13/2018

Oncology

News

Leukemic Transformation in MPNs a Major Challenge for Clinicians

02/20/2018

There is no standard of care treatment option for patients with leukemic transformation in myeloproliferative neoplasms, though new approaches may provide practice-changing strategies.

There is no standard of care...

02/20/2018

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology